International Journal of Pharmaceutics
Total Page:16
File Type:pdf, Size:1020Kb
INTERNATIONAL JOURNAL OF PHARMACEUTICS AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.2 • Impact Factor p.2 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.5 ISSN: 0378-5173 DESCRIPTION . The International Journal of Pharmaceutics has an open access mirror journal International Journal of Pharmaceutics: X which has the same aims and scope and peer-review process. To submit to International Journal of Pharmaceutics: X visit https://www.editorialmanager.com/IJPHARMX/default.aspx. The International Journal of Pharmaceutics is the second most cited journal in the "Pharmacy & Pharmacology" category out of 358 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues. Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher. Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles. AUTHOR INFORMATION PACK 3 Oct 2021 www.elsevier.com/locate/ijpharm 1 AUDIENCE . Pharmaceutical Scientists, Clinical Pharmacologists, Chemical Engineers, Biotechnologists. IMPACT FACTOR . 2020: 5.875 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . PubMed/Medline CAB International Current Contents - Life Sciences and Clinical Medicine Elsevier BIOBASE International Pharmaceutical Abstracts BIOSIS Citation Index Chemical Abstracts Scopus Embase Pascal Francis Science Citation Index EDITORIAL BOARD . Editor-in-Chief Jürgen Siepmann, University of Lille Faculty of Pharmacy, 3 rue du Professeur Laguesse, 59006, Lille cedex, France Editors for North America Zhengrong Cui, The University of Texas at Austin Division of Molecular Pharmaceutics and Drug Delivery, 2409 University Ave., A1900, 78712-0120, Austin, Texas, United States of America for Japan and Far East Yongzhuo Huang, Shanghai Institute of Materia Medica Chinese Academy of Sciences, 199 Guo Shou Jing Rd.,, 201203, Shanghai, China Fumiyoshi Yamashita, Kyoto University Graduate School of Pharmaceutical Sciences, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, Japan Sung-Joo Hwang, Yonsei University College of Pharmacy, 85 Songdogwahak-ro, 21983, Incheon, Yeonsu-gu, South Korea for Rest of the World Carmen Alvarez-Lorenzo, Universidade de Santiago de Compostela Faculty of Pharmacy, School Of Pharmacy Campus Vida, 15782, Santiago de Compostela, Spain Abdul Basit, University College London School of Pharmacy, 29-39 Brunswick Square, WC1N 1AX, London, United Kingdom Leena Peltonen, University of Helsinki, 00014, Helsinki, Finland Adriana R. Pohlmann, Universidade Federal do Rio Grande do Sul Programa de Pós-Graduação em Ciências Farmacêuticas, PORTO ALEGRE, Brazil Raymond Schiffelers, University Medical Centre Utrecht Laboratory of Clinical Chemistry and Haematology, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands for Reviews Juan M. Irache, University of Navarre Department of Technological Pharmacy and Pharmacy Chemistry, Irunlarrea, 1, E-31080, Pamplona, Spain Editorial Board Göran Alderborn, Uppsala University Faculty of Pharmacy, Uppsala, Sweden Eric Allémann, University of Geneva Faculty of Science, Geneva, Switzerland Maria Josè Alonso, Universidade de Santiago de Compostela Faculty of Pharmacy, Santiago de Compostela, Spain AUTHOR INFORMATION PACK 3 Oct 2021 www.elsevier.com/locate/ijpharm 2 Karim Amighi, ULB Faculty of Pharmacy, Bruxelles, Belgium Oral, Parenteral, Lung and Nasal Drug Delivery, Drug Targeting, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Lung Aspergillosis, Cancer, Monoclonal Antibodies, Nanobodies. David Attwood, The University of Manchester Division of Pharmacy and Optometry, Manchester, United Kingdom Patrick F. Augustijns, Katholieke Universiteit Leuven Farmacotechnologie en Biofarmacie, Leuven, Belgium Gillian Barratt, Paris-Saclay University Faculty of Pharmacy, Chatenay Malabry, France Ruggero Bettini, University of Parma Department of Biosciences, Parma, Italy Maria Blanco-Prieto, University of Navarra, Navarra, Spain Paolo Blasi, University of Bologna Department of Pharmacy and Biotechnology, Bologna, Italy Pharmaceutical nanotechnology, Brain drug delivery, Lung delivery, Cell encapsulation Roland Bodmeier, Free University of Berlin Faculty of Biology Chemistry Pharmacology, Berlin, Germany Ben J. Boyd, Monash University, Clayton, Victoria, Australia Hak-Kim Chan, The University of Sydney School of Pharmacy, Sydney, Australia Han-Gon Choi, Hanyang University Institute of Pharmaceutical Science and Technology, Ansan, South Korea Paolo Colombo, University of Parma Department of Pharmacy, Parma, Italy Duncan Craig, University College London School of Pharmacy, London, United Kingdom Daan Crommelin, Utrecht University Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands Drug Targeting, Liposomes, Controlled Release. Shyamal Chandra Das, University of Otago New Zealand's National School of Pharmacy, Dunedin, New Zealand Respiratory Drug Delivery, Dissolution, Surface Energy, Tuberculosis, Dry Powder Inhaler Giuseppe De Rosa, University of Naples Federico II, Via Cintia, Naples, Italy Dominique Duchêne, Paris-Saclay University Faculty of Pharmacy, Chatenay Malabry, France Julia Engert, Ludwig Maximilian University Munich Department of Pharmacy, Munchen, Germany Brigitte Evrard, University of Liege Department of Pharmaceutical Sciences, Liege, Belgium Anna Maria Fadda, University of Cagliari Department of Life Sciences and Environment, Cagliari, Italy Elias Fattal, Paris-Saclay University Faculty of Pharmacy, Chatenay Malabry, France Jim Ford, Liverpool John Moores University School of Pharmacy and Biomolecular Sciences, Liverpool, United Kingdom Simon Gaisford, University College London School of Pharmacy, London, United Kingdom Huile Gao, Sichuan University Key Laboratory of Drug Targeting and Drug Delivery System, Chengdu, China Drug delivery systems, nanoparticles, tumor microenvironment, brain targeting delivery Andrea Gazzaniga, University of Milan Department of Pharmaceutical Sciences, Milano, Italy Achim Goepferich, University of Regensburg Faculty of Chemistry and Pharmacy, Regensburg, Germany Richard H. Guy, University of Bath Department of Pharmacy and Pharmacology, Bath, United Kingdom Jonathan Hadgraft, University College London School of Pharmacy, London, United Kingdom Hideyoshi Harashima, Hokkaido University Faculty of Pharmaceutical Sciences, Sapporo, Japan Research Expertise: Gene delivery, nanomedicine, microfluidics, cancer immunology, mitochondria, BBB. Masahiro Hayashi, Tokyo University of Pharmacy and Life Science School of Pharmacy Department of Biopharmaceutics, Hachioji, Japan Paul W. S. Heng, National University of Singapore Department of Pharmacy, Singapore, Singapore Yogeshvar Kalia, University of Geneva School of Pharmaceutical Sciences, Geneva, Switzerland Topical &, , Transdermal Delivery, Ocular Delivery, Intestinal Absorption, Formulation, Polymeric micelles Mansoor Khan, Center for Drug Evaluation and Research Office of Medical Policy, Silver Spring, Maryland, United States of America Peter Kleinebudde, Heinrich Heine University Düsseldorf Institute of Pharmaceutics and Biopharmaceutics, Düsseldorf, Germany Gaetano Lamberti, University of Salerno Department of Industrial Engineering, Fisciano, Italy Majella E. Lane, University College London School of Pharmacy, London, United Kingdom Anette Larsson, Chalmers University of Technology Applied Chemistry, Gothenburg, Sweden Panos Macheras, National and Kapodistrian University of Athens Department of Pharmaceutical Technology, Athens, Greece Karsten Mäder, Martin Luther University Halle-Wittenberg Department of Pharmacy, Halle, Germany Biodegradable Polymers; In Vivo, Nanoparticles, Implants, Microparticles Ashim Mitra, University